<code id='89EEE9CFDF'></code><style id='89EEE9CFDF'></style>
    • <acronym id='89EEE9CFDF'></acronym>
      <center id='89EEE9CFDF'><center id='89EEE9CFDF'><tfoot id='89EEE9CFDF'></tfoot></center><abbr id='89EEE9CFDF'><dir id='89EEE9CFDF'><tfoot id='89EEE9CFDF'></tfoot><noframes id='89EEE9CFDF'>

    • <optgroup id='89EEE9CFDF'><strike id='89EEE9CFDF'><sup id='89EEE9CFDF'></sup></strike><code id='89EEE9CFDF'></code></optgroup>
        1. <b id='89EEE9CFDF'><label id='89EEE9CFDF'><select id='89EEE9CFDF'><dt id='89EEE9CFDF'><span id='89EEE9CFDF'></span></dt></select></label></b><u id='89EEE9CFDF'></u>
          <i id='89EEE9CFDF'><strike id='89EEE9CFDF'><tt id='89EEE9CFDF'><pre id='89EEE9CFDF'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:29946
          wastewater testing
          Adobe

          Alphabet’s life sciences company Verily has scored its first Centers for Disease Control and Prevention contract, a high profile job leaders hope will boost its brand in public health as well as its nascent wastewater surveillance business, executives told STAT.

          Under the up-to-five year, $38 million contract, Verily will collect samples from hundreds of wastewater treatment centers across the country, analyze them for Covid-19 and the mpox virus at its South San Francisco lab, and return the data to CDC within 36 hours of collecting the samples. The contract is limited to those two pathogens but the company is prepared to analyze more if needed, leaders said.

          advertisement

          The contract comes as Verily struggles to turn a profit among various disparate health care offerings, like value-based care analytics for health systems, clinical trial software and even an in-person substance use rehabilitation center in Ohio. Despite several prominent hires and a vast number of projects, the company has yet to forge a sustainable business.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Do masks work? RCTs can't tell us
          Do masks work? RCTs can't tell us

          MarkLennihan/APEarlyintheCovid-19pandemic,beforewehadvaccinesandeffectivemedicalprocedures,theonlywa

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          For BCIs, commercial hurdles may be bigger than scientific ones

          AdevicecomponentfromParadromicsInc.,oneofthemainbrain-computerinterfaceplayersracingtogettomarket.Co